Canada markets close in 2 hours 50 minutes

DIAGNOS Inc. (ADK.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.28000.0000 (0.00%)
As of 12:29PM EDT. Market open.
Full screen
Previous Close0.2800
Open0.2850
Bid0.2750 x 0
Ask0.2950 x 0
Day's Range0.2750 - 0.3000
52 Week Range0.1000 - 0.3200
Volume403,300
Avg. Volume175,006
Market Cap17.182M
Beta (5Y Monthly)1.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.75
  • GlobeNewswire

    DIAGNOS Welcomes Mr. Vincent Duhamel and Mr. Robert J. Dunn to its Board of Directors

    BROSSARD, Quebec, Sept. 28, 2020 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), is pleased to announce the appointments of Mr. Vincent Duhamel and Mr. Robert J. Dunn to the Corporation’s board of directors (the “Board”). Mr. Duhamel has an established track record in overseeing start-up companies and restructuring operations, as well as leading large investment teams in multi-cultural environments. Mr. Duhamel is Vice Chairman of the board of directors of Fiera Capital, a leading independent global asset management firm. Prior to joining Fiera Capital, he held several senior positions in Asia and Canada. Mr. Duhamel has played an active role on several boards and committees, including at the CFA Institute and the Stock Exchange of Hong Kong.With 40 years of extensive experience in the insurance business, Mr. Dunn brings expertise in, among others, the financial and communications sectors. From 2017 to 2019, Mr. Dunn held the position of Vice Chairman and Executive Vice President of HUB International Québec Ltd.“We are pleased that Vincent and Robert have accepted to join the Board. I am convinced that their vast work experience and business relationships will directly contribute to the growth and success of our business,” said Mr. André Larente, President of DIAGNOS.The Board has approved a grant of 600,000 stock options to Mr. Duhamel and a grant of 500,000 stock options to Mr. Dunn. Stock options vest at 50% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.285 per share. The expiry date to which these options can be exercised has been fixed to September 28, 2025.Furthermore, the Corporation announces the resignation of Mr. Georges Hébert from his position as director and chairman of the audit committee. The Board wishes to thank Mr. Hébert for his contribution to the development of DIAGNOS.The Corporation also announces that, subject to regulatory acceptance, at the annual and special meeting of shareholders held earlier today, the disinterested shareholders of the Corporation approved a special resolution pursuant to which the maximum number of common shares of the Corporation that may be issued under the stock option plan be set at 9,000,000, representing an increase of 3,000,000 common shares.About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet, and is compatible with all recognized image formats and brands of fundus cameras, and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America, is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.Additional information is available at www.diagnos.com and www.sedar.comThis news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca

  • GlobeNewswire

    DIAGNOS Announces a Multi-Year Contract with Chaparral Medical Group in California

    BROSSARD, Quebec, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or “the Corporation”) (TSX Venture: ADK, OTCQB: DGNOF), a leader in early detection of critical health issues through the use of Artificial Intelligence (AI), announces today the signing of a three-year agreement with its US based client, Chaparral Medical Group (“Chaparral”). “By working closely with Chaparral, we have developed a new business model for one of our key markets, the US. Chaparral is a very high value referral account with the best practice in healthcare. We are very proud to renew our agreement with the full consent of Chapparal’s top management. Now is the time to build on our market growth and increase our market share of diabetic retinopathy screening,’’ said André Larente, CEO of DIAGNOS.Yearly eye exams for diabetic patients are a common requirement guideline of almost all Endocrinology Society and Medical Diabetic Associations around the world. Our CARA (Computer Assisted Retinal Analysis) platform at Chaparral will help to meet this high value requirement. Higher compliancy with diabetes disease management means: * Reduction in blindness, amputations and stage renal disease propensity * Increase in quality adjusted life years per patient * Significant reduction on care cost with less Emergency Room visits, less days of hospitalization and fewer claims * Better HEDIS (Healthcare Effectiveness Data and Information Set) scores and increase in (RAF) Risk Adjustment Factor scores for ChaparralDr. Prasad, diabetes specialist, President and Medical Director of Chaparral Medical Group stated: “We are pleased to re-engage with DIAGNOS for another three years, validating the mutually beneficial relationship between our two companies. With a retinal scan, we can identify cases of diabetes by having an eye exam 10 years before the complications arise. And if detected early, we can treat it and reduce the incidence of blindness. With the Computer Assisted Retinal Analysis (CARA) Platform, DIAGNOS is also playing a key role in our “Diabetic Champion Program”. With it, we can quickly screen our large community of diabetic patients for any signs of diabetic retinopathy.” Chaparral is a proud award recipient of "The American Diabetes Association and National Committee for Quality Assurance” Achievement of Recognition for delivery of Quality Diabetes Care.About Chaparral Chaparral Medical Group is a 60 physician multi-specialty group serving in 23 clinics in the communities of Claremont, La Verne, San Dimas, Fontana, Pomona, Rancho Cucamonga, Upland, Chino Hills and Diamond Bar in Southern California. Over 20 primary care physicians serve as the group’s clinical core, and work together with their medical and surgical specialists to provide outstanding care to the patient population of Southern California. The Company has been serving the community since 1978 and its unwavering commitment to patient care and physician work satisfaction are what have driven it to become the most trusted and relied-upon group of physicians in their area.About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.Additional information is available at www.diagnos.com and www.sedar.com.This news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information, please contact:Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca

  • GlobeNewswire

    DIAGNOS Receives $2,000,000 Assistance from Quebec

    BROSSARD, Quebec, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK) (OTCQB: DGNOF), a leader in early detection of critical health issues using advanced Artificial Intelligence (AI), is pleased to announce the signing of a financing agreement in the form of an interest-free loan of up to $2,000,000 from the government of Québec via the Economic Development Fund to support the commercialization of CARA globally. "Thanks to this financial assistance from the government of Quebec, we will be able to accelerate the commercialization of CARA in markets where the prevalence of diabetes and its complications is high. Among other things, teams of professionals dedicated to marketing and commercialization will be set up to cover each of these markets. We would like to thank the people of the government and Investissement Québec for their trust in our team and our innovative screening technology for diabetic retinopathy, a disease that can cause blindness if left untreated", said André Larente, President of DIAGNOS.The CARA's commercialization project is valued at $4,065,710. Under the financing agreement, loan disbursement will be made in installments corresponding to 49% of the eligible expenses incurred up to June 30, 2022 for which the Corporation is requesting disbursement, up to $2,000,000. The interest-free loan has a term of 10 years and principal repayment will start after the 24th month following the first disbursement. The Corporation estimates that it will avoid up to $1,350,000 in financing costs due to the loan being interest-free.The Corporation also announces that last April it had undertaken a cost-reduction exercise to reduce its fixed operating costs through layoffs and the negotiation of a new lease agreement for its head office. Taking into account governmental aid programs related to Covid-19, the Corporation's disbursements have been reduced by nearly 50% from the pre-pandemic level.About DIAGNOS DIAGNOS is a publicly-traded Canadian corporation with a mission of early detection of critical health issues through the use of its Artificial Intelligence (“AI”) tool CARA (Computer Assisted Retina Analysis). CARA is a tele-ophthalmology platform that integrates with existing equipment (hardware and software) and processes at the point of care. CARA’s Artificial Intelligence image enhancement algorithms make standard retinal images sharper, clearer and easier to read. CARA is accessible securely over the internet and is compatible with all recognized image formats and brands of fundus cameras and is EMR compatible. CARA is a cost-effective tool for screening large numbers of patients in real-time. CARA complies with local regulations, is FDA cleared for commercialization in the United States of America is Health Canada licensed for commercialization in Canada and is CE marking compliant in Europe.Additional information is available at www.diagnos.com and www.sedar.comThis news release contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements. DIAGNOS disclaims any intention or obligation to publically update or revise any forward-looking information, whether as a result of new information, future events or otherwise. The forward-looking information contained in this news release is expressly qualified by this cautionary statement.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information about this press release, please contact: Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca